Recently it was demonstrated that combining a pan PI3K inhibitor (XL 147) with Herceptin may overcome herceptin-resistance in breast cancer by suppressing HER2/PI3K/FOXO/survivin signaling [278]. The gene discussed is ERBB2; the disease is breast carcinoma.